Clinical trials
Completed Phase 1 Alcoholism trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
72 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 8 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 6 |
| 2015 | 3 |
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 7 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 72 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Yale University | 10 |
| Brown University | 8 |
| GlaxoSmithKline | 4 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 4 |
| Medical University of South Carolina | 3 |
| Alkermes, Inc. | 2 |
| Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2 |
| Pop Test Oncology LLC | 2 |
| Rajesh Narendran | 2 |
| University of Maryland, Baltimore | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alcoholism | 72 |
| Substance-Related Disorders | 11 |
| Alcohol-Related Disorders | 6 |
| Stress Disorders, Post-Traumatic | 3 |
| Anxiety Disorders | 2 |
| Chemically-Induced Disorders | 2 |
| Inflammation | 2 |
| Acquired Immunodeficiency Syndrome | 1 |
| Alcohol Withdrawal Delirium | 1 |
| Attention Deficit Disorder with Hyperactivity | 1 |
Trials
Showing 1 to 25 of 72. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.